C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
C4 Therapeutics (Nasdaq: CCCC) announced that the European Society for Medical Oncology (ESMO) Congress has upgraded their previously accepted preliminary Phase 1 abstract for CFT1946, a novel BiDAC™ degrader for mutant BRAF V600 solid tumors, to an oral presentation. The presentation is scheduled for September 13, 2024, at 4:00 pm to 5:30 pm CEST. Dr. Maria Vieito from Barcelona will present the preliminary results from the Phase 1 study. C4T will also host an investor webcast on the same day to discuss the CFT1946 monotherapy data from the ongoing trial. This change in presentation format suggests increased interest in C4T's research, potentially indicating promising preliminary results for their targeted protein degradation approach in oncology.
C4 Therapeutics (Nasdaq: CCCC) ha annunciato che il Congresso della Società Europea di Oncologia Medica (ESMO) ha aggiornato il loro precedente abstract preliminare della Fase 1 per CFT1946, un nuovo degrader BiDAC™ per i tumori solidi mutanti BRAF V600, a una presentazione orale. La presentazione è programmata per il 13 settembre 2024, dalle 16:00 alle 17:30 CEST. Il Dr. Maria Vieito di Barcellona presenterà i risultati preliminari dello studio di Fase 1. C4T ospiterà anche un webcast per gli investitori lo stesso giorno per discutere i dati della monoterapia CFT1946 provenienti dallo studio in corso. Questa modifica nel formato della presentazione suggerisce un interesse crescente nella ricerca di C4T, potenzialmente indicando risultati preliminari promettenti per il loro approccio di degradazione proteica mirata in oncologia.
C4 Therapeutics (Nasdaq: CCCC) anunció que el Congreso de la Sociedad Europea de Oncología Médica (ESMO) ha actualizado su anterior resumen preliminar de la Fase 1 para CFT1946, un nuevo degrader BiDAC™ para tumores sólidos mutantes BRAF V600, a una presentación oral. La presentación está programada para el 13 de septiembre de 2024, de 16:00 a 17:30 CEST. La Dra. Maria Vieito de Barcelona presentará los resultados preliminares del estudio de la Fase 1. C4T también realizará un webcast para inversores el mismo día para discutir los datos de la monoterapia CFT1946 del ensayo en curso. Este cambio en el formato de presentación sugiere un interés creciente en la investigación de C4T, lo que potencialmente indica resultados preliminares prometedores para su enfoque de degradación proteica dirigida en oncología.
C4 Therapeutics (Nasdaq: CCCC)는 유럽종양내과학회(ESMO) 학술대회가 CFT1946에 대한 기존의 1상 초록을 구두 발표로 업그레이드했다고 발표했습니다. CFT1946는 V600 돌연변이 BRAF 고형 암 종양을 위한 새로운 BiDAC™ 분해제입니다. 발표는 2024년 9월 13일, 오후 4시부터 5시 30분까지 CEST에 예정되어 있습니다. 바르셀로나의 마리아 비에이토 박사가 1상 연구의 초기 결과를 발표할 예정입니다. C4T는 또한 같은 날 투자자 웹캐스트를 열어 진행 중인 시험의 CFT1946 단독 요법 데이터에 대해 논의할 것입니다. 발표 형식의 변경은 C4T의 연구에 대한 증가된 관심을 시사하며, 이는 온콜로지에서의 목표 단백질 분해 접근법에 대해 유망한 초기 결과를 나타낼 수 있습니다.
C4 Therapeutics (Nasdaq: CCCC) a annoncé que le Congrès de la Société Européenne d'Oncologie Médicale (ESMO) a reclassé leur précédent résumé préliminaire de la Phase 1 pour CFT1946, un nouveau degrader BiDAC™ pour les tumeurs solides BRAF V600 mutantes, en une présentation orale. La présentation est prévue pour le 13 septembre 2024, de 16h00 à 17h30 CEST. Dr. Maria Vieito de Barcelone présentera les résultats préliminaires de l'étude de la Phase 1. C4T organisera également un webinaire pour les investisseurs le même jour pour discuter des données du monothérapie CFT1946 issues de l'essai en cours. Ce changement de format de présentation suggère un intérêt croissant pour la recherche de C4T, ce qui pourrait indiquer des résultats préliminaires prometteurs pour leur approche de dégradation ciblée des protéines en oncologie.
C4 Therapeutics (Nasdaq: CCCC) gab bekannt, dass der Europäische Kongress für Medizinische Onkologie (ESMO) ihr zuvor angenommenes vorläufiges Abstract der Phase 1 für CFT1946, einen neuartigen BiDAC™ Degrader für mutante BRAF V600 solide Tumoren, auf eine mündliche Präsentation hochgestuft hat. Die Präsentation ist für den 13. September 2024, von 16:00 bis 17:30 Uhr CEST geplant. Dr. Maria Vieito aus Barcelona wird die vorläufigen Ergebnisse der Phase 1 Studie präsentieren. C4T wird am selben Tag auch ein Webcast für Investoren veranstalten, um die Monotherapie-Daten von CFT1946 aus der laufenden Studie zu erörtern. Diese Änderung des Präsentationsformats deutet auf ein wachsendes Interesse an den Forschungen von C4T hin und könnte vielversprechende vorläufige Ergebnisse für ihren Ansatz der gezielten Proteindegradation in der Onkologie anzeigen.
- Upgrade of presentation format from abstract to oral presentation at ESMO Congress
- Increased visibility for CFT1946, C4T's novel BiDAC™ degrader for BRAF V600 solid tumors
- Scheduled investor webcast to discuss CFT1946 monotherapy data
- None.
Investor Webcast Moved to Friday, September 13, 2024
WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the ESMO Congress decided to move C4T’s previously accepted preliminary monotherapy Phase 1 abstract for CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, to an oral presentation. This oral presentation session at the ESMO Congress 2024 is scheduled for Friday, September 13, 2024, at 4:00 pm to 5:30 pm CEST. Additionally, C4T announced it will host an investor webcast on Friday, September 13, 2024.
Updated Details for ESMO Congress 2024 Presentation
Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BiDAC™ Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: Friday, September 13, 2024, 4:00 – 5:30 pm CEST
Final Publication Number: 612O
Presenter: Maria Vieito, M.D., Msc (Barcelona, Spain)
C4T Webcast for Analysts and Investors
C4T will host an investor webcast on Friday, September 13, 2024 to discuss the CFT1946 monotherapy data from ongoing CFT1946 Phase 1 trial in BRAF V600 solid tumors. The time of the webcast and access information will be shared closer to the webcast event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
About CFT1946
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including colorectal cancer, melanoma and non-small cell lung cancer. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
What is the new presentation format for C4 Therapeutics' CFT1946 at ESMO Congress 2024?
What is CFT1946 and what is it being developed for by C4 Therapeutics (CCCC)?
When will C4 Therapeutics (CCCC) host its investor webcast to discuss CFT1946 data?
Who will present the CFT1946 Phase 1 study results at ESMO Congress 2024?
